Drugs from a class called tyrosine kinase inhibitors have become standard treatments for some cancers, but the improved survival of patients taking these medicines introduces a new problem. As ...

Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported ...

Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder-based, pre-revenue oncology drug developer, grew its expenses and net losses in the fourth quarter of 2023 and for the full 2023 fiscal year as two ...

Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale ...

BOULDER, Colo., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Pegozafermin sustained statistically significant ...

BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small ...